Tirzepatide vs Semaglutide for PCOS: Which Is Right for You?

If you have PCOS and you're weighing tirzepatide against semaglutide, here's the short version: both can help, but they lead with different strengths. Semaglutide has more published PCOS-specific research on menstrual cycles, ovulation, and androgens. Tirzepatide tends to produce more total weight loss in head-to-head studies. Neither is FDA-approved for PCOS, so both are used off-label, and the right choice depends on your goal, how your body tolerates side effects, and cost. A licensed provider should help you decide.

Key takeaways

• Semaglutide (the molecule in Wegovy and Ozempic) has the deeper bench of PCOS-focused studies, including data on restoring regular periods.
• Tirzepatide (the molecule in Zepbound and Mounjaro) generally drives greater overall weight loss, which itself improves many PCOS symptoms.
• Neither is FDA-approved for PCOS. Wegovy and Zepbound are approved for weight management; Ozempic and Mounjaro are approved for type 2 diabetes. PCOS use is off-label for all of them.
• Both outperform metformin for weight loss in women with PCOS in recent real-world data.
• The best pick depends on your priority (cycle and fertility support vs. maximum weight loss), your side-effect tolerance, and budget, a decision to make with a clinician.

How do GLP-1s help PCOS in the first place?

PCOS is driven largely by insulin resistance and excess weight, which push the ovaries to make more androgens (like testosterone). Higher androgens are what fuel irregular or missing periods, acne, and unwanted hair growth. When you improve insulin sensitivity and lose weight, that cycle often loosens, periods can become more regular, ovulation can return, and androgen symptoms can ease.

Semaglutide and tirzepatide are both GLP-1-based medications. Semaglutide activates the GLP-1 receptor; tirzepatide activates two receptors, GIP and GLP-1. Both slow how fast your stomach empties, reduce appetite, and improve blood-sugar control. For PCOS, the knock-on effects on insulin and weight are the point, the reproductive benefits mostly follow from there.

Which has more PCOS-specific evidence?

Semaglutide does. More published studies have looked specifically at semaglutide in women with PCOS, and several report improvements in menstrual regularity. In one 2023 study of 27 obese women with PCOS who hadn't responded to lifestyle changes, low-dose semaglutide produced a mean weight loss of about 11.5 kg over six months, and roughly 80% of the women who responded to treatment saw their menstrual cycles normalize. That's a small study, and "responders" is a narrower group than everyone who started, so read it as encouraging rather than a guarantee.

Tirzepatide is newer, so its PCOS-specific research base is thinner today. Much of the case for tirzepatide in PCOS is extrapolated from its weight-loss power, because losing weight and improving insulin sensitivity are the main levers in PCOS, and tirzepatide is very effective at both. Expect the tirzepatide-PCOS evidence to grow over the next few years.

Which one leads to more weight loss?

Tirzepatide, in the studies done so far. In the STEP 1 trial, adults on semaglutide 2.4 mg lost about 14.9% of body weight over 68 weeks. In the SURMOUNT-1 trial, adults on the top tirzepatide dose (15 mg) lost about 20.9% over 72 weeks. A 2024 head-to-head analysis in JAMA Internal Medicine comparing real-world patients also found people on tirzepatide were more likely to reach meaningful weight-loss milestones than those on semaglutide.

Those trials weren't PCOS-specific, but they're the best apples-to-apples weight-loss comparison available. For a woman whose main goal is the largest possible weight reduction, tirzepatide has the edge on paper.

GLP-1 vs metformin for PCOS, where do these fit?

Metformin has long been a first step for PCOS, but the newer GLP-1 data are striking. In a 2025 Epic Research analysis of more than 36,000 women with PCOS, those prescribed a GLP-1 lost a median 11.5% of body weight at one year, versus 1.9% on metformin. More than half, 55.7%, of the GLP-1 group lost at least 10% of their weight, compared with 13.7% of the metformin group. GLP-1 users were also more likely to see their A1C (a blood-sugar marker) improve.

This doesn't mean metformin is obsolete, it's inexpensive, well understood, and sometimes used alongside a GLP-1. But for weight loss specifically, GLP-1 medications clearly outperformed it in this group.

Tirzepatide vs semaglutide for PCOS: side-by-side

Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.

A simple way to think about the choice

There's no universally "better" drug, there's a better fit for you. A few questions that tend to point one way or the other:

• Is regulating your cycle or supporting fertility your top priority? Semaglutide has more direct PCOS-reproductive data behind it today, which some women and providers find reassuring. (If pregnancy is on your radar, note that GLP-1s are not used in pregnancy and should be stopped well before trying to conceive, a conversation to have early with your provider.)
• Is maximum weight loss the main goal? Tirzepatide produced more weight loss in the trials above, and since weight is the central lever in PCOS, that often translates into broad symptom improvement.
• Are you on the pill? Tirzepatide's FDA label warns it can make oral birth control less effective, so a backup or non-oral method is advised after starting and after each dose increase. Semaglutide carries no such warning. If you rely on the pill, this may steer your choice, see our full guide to tirzepatide and birth control.
• How's your side-effect tolerance and budget? Both cause similar GI effects (nausea, constipation), which usually ease with slow dose increases. Cost differs too, compounded tirzepatide runs meaningfully higher than compounded semaglutide.

What are the risks with either medication?

Both semaglutide and tirzepatide carry a boxed warning for thyroid C-cell tumors and are not for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Other cautions include pancreatitis, gallbladder problems, and significant nausea, vomiting, or diarrhea, especially while the dose is going up. Because PCOS overlaps with plans for pregnancy, it's worth repeating: these medications are not recommended in pregnancy or while breastfeeding.

This is why PCOS treatment isn't a self-serve decision. Talk to a licensed provider who can weigh your history, screen for contraindications, and choose and monitor the right medication and dose. For the full prescribing details, see the FDA information for Wegovy and Zepbound.

How Elara helps

Elara is built for exactly this decision. A licensed provider reviews every patient and helps you choose between compounded semaglutide and compounded tirzepatide, each prepared by a state-licensed compounding pharmacy and prescribed when it's appropriate for you, based on your PCOS picture: cycles, insulin resistance, weight goals, birth control, and pregnancy plans, not a one-size-fits-all script. We serve all 50 states plus Puerto Rico, and our pricing is cash-pay and all-inclusive: the provider visit, your medication, shipping, ongoing access to our medical team, the Elara app, and the community are all in one price. No insurance hurdles, no surprise fees.

Brand-name Wegovy lists around $1,349 a month (NovoCare); Elara's compounded semaglutide program starts at $247/month, all-in, and compounded tirzepatide starts at $355/month. Compounded medications are not FDA-approved. (The rules here are still evolving: on April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, a proposed action, not a final rule.) If you want the deeper dives, read our women's guides to semaglutide and tirzepatide, or the complete GLP-1 for PCOS guide.

See which GLP-1 fits your PCOS, take Elara's free eligibility check. A licensed provider reviews every patient. Compounded medications are not FDA-approved.

Frequently asked questions

Is tirzepatide or semaglutide better for PCOS? Neither is objectively "better", it depends on your goal. Semaglutide has more published PCOS-specific research on cycles and ovulation, while tirzepatide tends to produce greater overall weight loss. Both are used off-label for PCOS. A licensed provider can match the medication to your priorities and health history.

Does semaglutide help you ovulate with PCOS? It can, indirectly. By improving insulin sensitivity and supporting weight loss, semaglutide lowers the androgens that disrupt ovulation, so some women see more regular cycles. In one small 2023 study, about 80% of women with PCOS who responded to semaglutide had their menstrual cycles normalize. Individual results vary; talk to your provider.

Is Wegovy approved for PCOS? No. Wegovy (semaglutide) is FDA-approved for chronic weight management, not for PCOS. No GLP-1 medication is FDA-approved specifically to treat PCOS, so any use for PCOS is off-label. That's a normal and legal practice, but it should always be guided and monitored by a licensed clinician.

GLP-1 vs metformin for PCOS, which works better for weight? For weight loss, recent data favor GLP-1s. In a 2025 Epic Research analysis of over 36,000 women with PCOS, GLP-1 users lost a median 11.5% of body weight at one year versus 1.9% on metformin, and far more reached at least 10% loss. Metformin is still useful and sometimes combined with a GLP-1.

Which is better for PCOS weight loss specifically? Tirzepatide produced more weight loss than semaglutide in trials and in a 2024 head-to-head analysis, so it has the edge when maximum weight reduction is the goal. But semaglutide is highly effective too and may suit women focused on cycle regularity or cost. The best choice is individualized with a provider.

The bottom line

For PCOS, semaglutide brings more cycle-and-ovulation research to the table, while tirzepatide brings more raw weight loss, and both beat metformin for shedding weight. Because neither is FDA-approved for PCOS and both carry real risks, the smart move isn't picking a "winner" online; it's letting a licensed provider match the medication to your body and your goals.

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. Rodriguez PJ, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine. 2024. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080
4. Epic Research. GLP-1s Lead to Greater Weight Loss and A1C Improvement Than Metformin in Patients with PCOS. 2025. https://www.epicresearch.org/articles/glp-1s-lead-to-greater-weight-loss-and-a1c-improvement-than-metformin-in-patients-with-pcos/
5. Carmina E, Longo RA. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. Journal of Clinical Medicine. 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531549/
6. U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
7. U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf
8. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
9. NovoCare. Wegovy (semaglutide) cost and coverage. https://www.novocare.com/patient/medicines/wegovy.html

This article is for general education and is not medical advice. Talk to a licensed clinician about your situation.

Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.